Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 12/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 11/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 11/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16972862 | 0.83 | GABRG2 (0.43) | GABRA5GABRG2GABRB3CYP11B2CYP11B1 | |
| SCHEMBL13178859 | 0.83 | GABRG2 (0.43) | GABRA5GABRG2GABRB3CYP11B2CYP11B1 | |
| SCHEMBL7318495 | 0.83 | GABRG2 (0.43) | GABRA5GABRG2GABRB3CYP11B2CYP11B1 | |
| SCHEMBL7323714 | 0.80 | GABRA5 (0.41) | GABRA5GABRG2GABRB3CYP11B2CYP11B1 | |
| SCHEMBL21603212 | 0.80 | GABRA5 (0.46) | GABRA5GABRG2GABRB3CYP11B2CYP11B1 | |
| SCHEMBL13140226 | 0.80 | TERT (0.36) | GABRA5GABRG2GABRB3CYP11B2CYP11B1 | |
| SCHEMBL16601586 | 0.80 | TSHR (0.38) | GABRA5GABRG2GABRB3TERTTSHR | |
| SCHEMBL21603242 | 0.79 | GABRA5 (0.45) | GABRA5GABRG2GABRB3CYP11B2CYP11B1 | |
| SCHEMBL18227101 | 0.78 | TERT (0.44) | GABRA5GABRG2GABRB3CYP11B2CYP11B1 | |
| SCHEMBL10203483 | 0.78 | TSHR (0.41) | GABRA5GABRG2GABRB3TERTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300943-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | US | disclosed |
| US-20210277015-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN-CILAG S.A. (ES) | 2021-09-09 | — | — | US | disclosed |
| WO-2019243527-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019243526-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| WO-2011151436-A2 | NOVEL COMPOUNDS, METHOD FOR USE THEM AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | EUROSCREEN S.A. (BE) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011151434-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300943-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | GABRA5 3015/4885GABRG2 2419/4885GABRB3 3176/4885 |
| US-20210277015-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | GABRA5 3015/4885GABRG2 2419/4885GABRB3 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.